Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate

Treatment of acute promyelocytic leukemia.

Treatment of acute promyelocytic leukemia.

Cure of acute promyelocytic leukemia (APL) is now a possibility for most patients through the use of state-of-the-art treatments, which include simultaneous administration of all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy for induction and consolidation, as well as ATRA-based maintenance. Risk-adapted strategies to modulate treatment intensity may be an effective approach t...

Targeting agents alone to cure acute promyelocytic leukemia.

n engl j med 369;2 nejm.org july 11, 2013 186 Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) that is characterized by abnormal promyelocytes, a lifethreatening bleeding syndrome, and t(15;17) chromosomal translocation. APL used to be the worst form of leukemia.1,2 The introduction of anthracycline-based chemotherapy in the 1970s yielded a complete remis...

Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure.

Acute promyelocytic leukemia (APL) is characterized by a specific t(15;17) chromosomal translocation that yields the PML/RARA fusion gene. Clinically, besides chemotherapy, two drugs induce clinical remissions: retinoic acid (RA) and arsenic trioxide (As). Both agents directly target PML/RARA-mediated transcriptional repression and protein stability, inducing to various extent promyelocyte diff...

Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia

Acute promyelocytic leukemia (APL) is a molecularly well-defined disease, characterized by a specific chromosomal translocation; the improvement in biologic and clinical knowledge and subsequent introduction of molecularly targeted therapies have transformed the management of APL, with survival rates now exceeding 80%. Minimal residual disease (MRD) assessment in APL is the most important tool ...